Article info
PDFTherapeutics/prevention
Cost-effectiveness study
Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection
- Correspondence to: Dr Diego Ripamonti, Infectious Diseases Unit, Azienda Ospedaliera Papa Giovanni XXIII, Piazza OMS 1, Bergamo 24127, Italy; diego.ripamonti{at}hotmail.com
Citation
Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection
Publication history
- First published August 26, 2016.
Online issue publication
May 20, 2020
Article Versions
- Previous version (20 May 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/